These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 33026)

  • 41. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disposition and metabolism of timiperone in the rat, dog, and monkey.
    Tachizawa H; Sudo K; Sasano H; Sano M
    Drug Metab Dispos; 1981; 9(5):442-8. PubMed ID: 6117443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Further studies on the metabolism of carbidopa, (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate, in the human, Rhesus monkey, dog, and rat.
    Vickers S; Stuart EK; Hucker HB
    J Med Chem; 1975 Feb; 18(2):134-8. PubMed ID: 804550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.
    Au WY; Dring LG; Grahame-Smith DG; Isaac P; Williams RT
    Biochem J; 1972 Aug; 129(1):1-10. PubMed ID: 4646774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The metabolism of l-N-benzyl- -methoxy-3-trifluoromethylphenethylamine hydrochloride in the rat, dog, monkey and man.
    Intoccia AP; Hwang B; Joseph G; Konicki G; Walkenstein SS
    Neuropharmacology; 1972 Nov; 11(6):761-75. PubMed ID: 4629346
    [No Abstract]   [Full Text] [Related]  

  • 46. N-Acetyl, 4-O-methyldopa, a major metabolite of L-4-O-methyldopa in man and rat.
    Mathieu P; Greffe J; Deruaz D; Guilluy R; Gjessing L
    Biochem Pharmacol; 1976 Mar; 25(5):497-500. PubMed ID: 942485
    [No Abstract]   [Full Text] [Related]  

  • 47. Method for measuring endogenous 3-O-methyldopa in urine and plasma.
    Armando I; Grossman E; Hoffman A; Goldstein DS
    J Chromatogr; 1991 Jul; 568(1):45-54. PubMed ID: 1770109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute configuration of alpha-methyldopamine formed metabolically from alpha-methyldopa in man.
    Marshall KS; Castagnoli N
    J Med Chem; 1973 Mar; 16(3):266-70. PubMed ID: 4733109
    [No Abstract]   [Full Text] [Related]  

  • 49. Unexpected adduct ion formation under chemical ionization conditions.
    Musson DG; Halldin MM; Karashima D; Castagnoli N
    Biomed Environ Mass Spectrom; 1986 Jun; 13(6):287-91. PubMed ID: 2943343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [PHENOLIC ACID AND INDOLE EXCRETION IN URINE FOLLOWING ADMINISTRATION OF ALPHA-METHYLDOPA].
    RUGE W; HARTMANN F
    Klin Wochenschr; 1963 Sep; 41():856-61. PubMed ID: 14121339
    [No Abstract]   [Full Text] [Related]  

  • 51. Demonstration of conjugated dopamine in monkey CSF by gas chromatography-mass spectrometry.
    Elchisak MA; Powers KH; Ebert MH
    J Neurochem; 1982 Sep; 39(3):726-8. PubMed ID: 7097278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of methyldopa in healthy man.
    Stenbaek O; Myhre E; Rugstad HE; Arnold E; Hansen T
    Eur J Clin Pharmacol; 1977 Oct; 12(2):117-23. PubMed ID: 923625
    [No Abstract]   [Full Text] [Related]  

  • 53. L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.
    Stocchi F; Vacca L; Grassini P; Pawsey S; Whale H; Marconi S; Torti M
    Parkinsons Dis; 2015; 2015():369465. PubMed ID: 26171276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa.
    Dobrinska MR; Kukovetz W; Beubler E; Leidy HL; Gomez HJ; Demetriades J; Bolognese JA
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):587-600. PubMed ID: 7182456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacokinetics of methyldopa.
    Myhre E; Rugstad HE; Hansen T
    Clin Pharmacokinet; 1982; 7(3):221-33. PubMed ID: 7047042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prodrugs. Do they have advantages in clinical practice?
    Stella VJ; Charman WN; Naringrekar VH
    Drugs; 1985 May; 29(5):455-73. PubMed ID: 3891303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa.
    Hu M; Subramanian P; Mosberg HI; Amidon GL
    Pharm Res; 1989 Jan; 6(1):66-70. PubMed ID: 2717522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prodrugs for the improvement of drug absorption via different routes of administration.
    Balant LP; Doelker E; Buri P
    Eur J Drug Metab Pharmacokinet; 1990; 15(2):143-53. PubMed ID: 2200683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat.
    Vickers S; Duncan CA; White SD; Breault GO; Royds RB; de Schepper PJ; Tempero KF
    Drug Metab Dispos; 1978; 6(6):640-6. PubMed ID: 33026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester.
    Vickers S; Duncan CA; Ramjit HG; Dobrinska MR; Dollery CT; Gomez HJ; Leidy HL; Vincek WC
    Drug Metab Dispos; 1984; 12(2):242-6. PubMed ID: 6144491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.